Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Allergan Clinical trial with TFC-1067??

<< Previous

Bullboard Posts

Next >>

Comment by biorunon Aug 01, 2023 9:46am

160 Views

Post# 35566656

RE:RE:Allergan Clinical trial with TFC-1067??

Very interesting. This seems to be the only way to get insight through great research and making the connections.

Part of the challenge for us is after the R&F debacle nobody believes anything so it results in 10 cents a share.

But the bottom line is that this new global licensing agreement with AbbVie - Allergan seems to be indicating that we are entering new territory on the planning and preparation phase for the eventual launch as one does the timeline analysis.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario